Rare disease & orphan access
Defend rare disease access when the trial is small and the price is high.
Knowledgeable builds rare disease and orphan drug access packages that anticipate the specific objections payers raise when populations are small, endpoints are surrogate and prices are premium, with every rebuttal grounded in the trial you ran, the natural history you can cite and the HTA precedents that actually apply.
Watch it run on your work.
Where this fits in your workflow.
Knowledgeable builds rare disease and orphan drug access packages that anticipate the specific objections payers raise when populations are small, endpoints are surrogate and prices are premium, with every rebuttal grounded in the trial you ran, the natural history you can cite and the HTA precedents that actually apply.
Most teams running Rare disease · Orphan today juggle a stack of search tools, PDF readers and consultancy slides, then spend the back half of the project reconciling claims to sources. Knowledgeable collapses that into one defensible workflow: defend rare disease access when the trial is small and the price is high.
The work runs against your literature, trial registries, HTA precedent, label and SmPC, with every sentence pinpoint-cited so your senior reviewer opens a document that's already at QC.
- 1Scope & comparator locked
- 2Evidence pulled & graded
- 3Draft built with citations
- 4QC pass against framework
The work that finally lands the way you scoped it.
Small-N methodology aware
Single-arm trials, external controls, surrogate endpoints and natural history addressed head-on, not hidden in the appendix.
Orphan HTA precedent library
NICE HST, G-BA orphan track, HAS ASMR for rare, Nordic council decisions, pre-mapped to your submission.
Multi-market bridging
One evidence base, adapted for the disparate rare disease frameworks across EU5+, US, Japan and Nordics.
Premium price defence
Rebuttals for the pricing objections that only land in rare, budget impact, IRP, managed entry agreements.
Bring the rare disease launch into one system.
Pressure-test a rare disease launchMore for market access & hta teams.
Built for orphan-grade scrutiny.
Every claim sourced, every methodological choice logged, EU residency. Ready for HTA, patient advocacy and payer.